The development of universal donor organs has been a long-standing goal in transplantation medicine, where the primary obstacles are immune rejection and the chronic shortage of compatible organs. Traditional transplantation relies on matching donor and recipient for human leukocyte antigens (HLA), but even with close matches, lifelong immunosuppression is required to prevent rejection. This approach is far from ideal, leading to significant morbidity and limiting the number of viable transplants. However, recent advances in CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) gene-editing technology are opening a new pathway toward creating organs that are immunologically invisible—organs that could be transplanted into any recipient without triggering a destructive immune response. By precisely editing the genome of donor animals, most notably pigs, scientists are now able to remove or modify the specific genes that cause hyperacute rejection, as well as address additional immune barriers. This article explores how CRISPR is being leveraged to develop universal donor organs, the key genes being targeted, current research progress, ethical considerations, and the challenges that remain before this technology can enter clinical practice.

Understanding CRISPR Technology

CRISPR is a gene-editing tool derived from a natural bacterial defense system. It consists of two main components: a guide RNA that directs the system to a specific DNA sequence, and a Cas protein (often Cas9) that acts as molecular scissors to cut the DNA at that precise location. Once cut, the cell’s natural repair mechanisms can be harnessed to either disrupt a gene (knockout) or insert a new sequence (knock-in). This technology has dramatically accelerated genetic research due to its relative simplicity, efficiency, and versatility compared to earlier methods like zinc-finger nucleases or TALENs. In the context of transplantation, CRISPR allows scientists to make multiple edits simultaneously—a key requirement for creating a universal donor organ, as several genetic modifications are needed to overcome the different layers of immune rejection.

The power of CRISPR lies not only in its precision but also in its scalability. Researchers can now engineer the genome of a pig embryo to lack multiple genes that trigger human immune responses, and these edits are heritable, enabling the creation of modified pig herds for organ harvesting. Over the past decade, CRISPR has moved from a laboratory curiosity to a tool with real-world therapeutic potential, and its application in xenotransplantation is one of the most promising frontiers. For a detailed overview of the CRISPR mechanism, the Nature Scitable resource provides an accessible introduction.

Why Pigs? The Preferred Animal Model

Pigs are considered the most suitable source for xenotransplantation due to anatomical and physiological similarities to humans, as well as their rapid breeding and scalability. Pig organs—heart, kidneys, liver, lungs—are roughly the same size as human organs, and their cardiovascular physiology is comparable. However, pigs carry certain genes that produce sugars and proteins on the surface of their cells that are recognized by the human immune system as foreign, leading to rapid rejection. The most notorious of these is a sugar called alpha-gal, which is absent in humans and other Old World primates but present on pig cells. Hyperacute rejection, which occurs within minutes to hours after transplantation, is primarily mediated by pre-existing human antibodies against alpha-gal. CRISPR has been used to knock out the gene responsible for producing alpha-gal (GGTA1), and this was one of the earliest successes in creating pig organs that can survive in a primate host. Additional modifications targeting other carbohydrate antigens and swine leukocyte antigens (SLA, the pig equivalent of HLA) are now being combined to create pigs with multiple genetic edits, often referred to as "multiplex" editing.

Key Genes Targeted for Universal Donor Organs

Alpha-1,3-Galactosyltransferase (GGTA1)

The GGTA1 gene encodes an enzyme that attaches alpha-gal sugars to cell surfaces. Knocking out GGTA1 eliminates the primary target for human pre-existing antibodies. This modification was a landmark achievement and is now standard in genetically engineered pig models for xenotransplantation. GGTA1-knockout pigs have been shown to avoid hyperacute rejection when their organs are transplanted into non-human primates, but additional barriers remain.

Cytidine Monophosphate-N-Acetylneuraminic Acid Hydroxylase (CMAH)

CMAH is responsible for producing a sugar called Neu5Gc, another xenoantigen that humans lack. Humans have circulating anti-Neu5Gc antibodies due to dietary exposure, so knocking out CMAH further reduces immune recognition. Many modern pig strains are double-knockouts for both GGTA1 and CMAH.

Beta-1,4-N-Acetylgalactosaminyltransferase 2 (B4GALNT2)

The B4GALNT2 gene adds another carbohydrate structure (Sda antigen) that is also immunogenic in humans. Triple-knockout pigs lacking GGTA1, CMAH, and B4GALNT2 are now being developed to cover the major xenoantigens. Research indicates that these triple-knockout organs are significantly better tolerated than single-knockout organs.

Swine Leukocyte Antigen (SLA) Class I and Class II

Beyond carbohydrate antigens, the pig major histocompatibility complex (MHC)—known as SLA—is a major target for cellular rejection. Human T cells can recognize SLA molecules and mount an immune attack. CRISPR can be used to knock out SLA class I and/or class II genes, effectively removing the primary targets for T cell-mediated rejection. However, complete knockout of MHC may also remove beneficial immune cells that help protect the organ from infection—a trade-off that researchers are carefully evaluating. Some strategies involve partially inactivating SLA expression or expressing human immune checkpoint proteins instead.

Additional Human-Compatible Modifications

To further dampen the immune response, researchers are inserting human transgenes into the pig genome. For example, inserting human complement regulatory proteins (CD46, CD55, CD59) helps protect pig cells from the human complement cascade. Inserting human thrombomodulin and TFPI can prevent coagulation abnormalities that occur when pig endothelium is exposed to human blood. Some advanced pig models now carry up to 10 or more genetic modifications, combining knockouts of xenoantigens with knock-ins of human protective genes. These multi-edited pigs are being used for pre-clinical studies in non-human primates, with encouraging survival rates of months rather than hours.

A comprehensive list of genes being targeted in xenotransplantation can be found in the review by Hryhorowicz et al. (2019) published in Frontiers in Immunology.

Current Research and Progress

Significant progress has been made in the last five years, culminating in the first experimental transplant of a genetically edited pig heart into a living human patient in January 2022 at the University of Maryland Medical Center. The pig had 10 genetic modifications: three knockouts to remove the major carbohydrate antigens (GGTA1, CMAH, B4GALNT2) and six human transgene insertions (CD46, CD55, CD47, human thrombomodulin, human heme oxygenase-1, and human endothelial protein C receptor). The patient, David Bennett, survived for two months with the heart functioning well before his condition deteriorated due to a complex combination of factors, including possible porcine cytomegalovirus reactivation and immune rejection. While the outcome was not a complete success, it provided invaluable data on the feasibility of using CRISPR-edited pig organs in humans.

In parallel, researchers at various institutions have achieved long-term survival of pig kidneys in non-human primates using combinations of genetic edits and immunosuppressive protocols. For instance, a team at Massachusetts General Hospital reported survival of pig kidneys with single GGTA1 knockouts plus human complement regulatory proteins for over a year in baboons, albeit with intensive immunosuppression. More recently, the addition of CD47 (a "don't eat me" signal) has further reduced phagocytosis of pig cells by human macrophages. These studies demonstrate that the concept of universal donor organs is moving from theory toward reality, though significant obstacles remain.

Outside of xenotransplantation, CRISPR is also being explored to edit human organs. For example, ex vivo perfusion systems could allow donated human organs to be gene-edited to remove or modify HLA genes, making them suitable for recipients regardless of HLA mismatch—a strategy known as "universal" human organ transplantation. This approach avoids the ethical complexities of using animal donors and could revolutionize the allocation of deceased donor organs. However, the technology is less advanced due to the limited availability of human organs and the need for rapid editing protocols that do not damage the organ.

Challenges to Overcome

Immune Rejection Beyond Xenogenic Barriers

Even with extensive genetic editing, the immune system is complex and redundant. Antibody-mediated rejection, T cell responses, and innate immunity all present challenges. Currently, even the most heavily edited pig organs still require significant immunosuppression in recipients, raising concerns about long-term safety and the risk of infection. The goal is to create organs that require minimal or no immunosuppression, but this has not yet been achieved.

Risk of Zoonotic Infections

Pigs harbor viruses that can infect human cells, most notably porcine endogenous retroviruses (PERVs). These are integrated into the pig genome and cannot be removed by conventional breeding. CRISPR has been used to inactivate all PERVs in pig cells by targeting their polymerase genes (the so-called PERV-C and PERV-A copies). However, proving that a pig is completely free of active PERVs and other unknown pathogens is difficult. The FDA and other regulatory bodies require extensive screening and containment measures to prevent cross-species transmission.

Safety and Stability of Multiple Gene Edits

Editing multiple genes in the same cell increases the risk of off-target mutations, chromosomal rearrangements, or unintended on-target effects. The long-term health of pigs carrying many edits is also a concern—some modifications could impair normal organ function or cause developmental abnormalities. Rigorous phenotyping of edited pigs is essential before organs are considered safe for human use. Furthermore, the efficiency of delivering CRISPR components to embryos or cells varies, and mosaicism (where only some cells carry the edit) can complicate the generation of homozygous lines.

Regulatory and Ethical Hurdles

Xenotransplantation using genetically modified animals raises ethical concerns about animal welfare, the modification of animal genomes, and the potential for unintended ecological consequences if animals were to escape. The ethics of using human subjects for initial trials, especially when conventional treatments are available (e.g., dialysis for kidney failure), are also debated. Regulatory frameworks are being developed by the FDA, the European Medicines Agency, and other bodies, but clear guidelines for clinical trials are still evolving. The 2022 pig heart transplant was conducted under a compassionate use authorization, not a formal clinical trial, highlighting the need for standardized protocols.

Ethical and Safety Considerations

The ethical landscape for CRISPR-edited universal donor organs is multifaceted. On the one hand, the potential to save thousands of lives each year is immense—the waiting list for organs in the US alone includes over 100,000 individuals, and many die before receiving a transplant. Xenotransplantation could offer an unlimited supply of organs, eliminating the need for deceased donors and reducing transplant tourism and illegal organ trade. On the other hand, the creation of pigs with human transgenes blurs species boundaries and raises questions about the moral status of these animals. Some argue that if pigs are being bred specifically for organ harvest, the genetic modifications could be seen as a continuation of existing farming practices, but the insertion of human genes makes the situation more complex. Public acceptance varies widely, and education about the benefits and risks is crucial.

From a safety perspective, the principal concern is the emergence of a novel disease from pig to human. PERVs are the most studied risk, but other pig pathogens (e.g., porcine cytomegalovirus, porcine lymphotropic herpesvirus) can also infect human cells. Rigorous screening of donor pigs, and potentially antiviral prophylaxis, will be necessary. Furthermore, the use of CRISPR in germline cells (pig embryos) results in heritable changes—a technology that is not permitted in humans for reproductive purposes, but is considered acceptable in animals for medical use under ethical oversight. Transparency in research, including detailed reporting of adverse events in animal studies and early human trials, will be essential to maintain public trust.

The World Health Organization (WHO) has established a dedicated program on xenotransplantation to provide international guidance and coordinate regulatory approaches, emphasizing ethical principles and safety standards.

Future Outlook and Conclusion

The path toward universal donor organs is still in its early stages, but the convergence of CRISPR technology, advances in immunology, and a deeper understanding of xenotransplantation barriers offer unprecedented optimism. In the near term (5–10 years), limited clinical trials of genetically modified pig kidneys and hearts are likely to begin, potentially as bridge therapies for patients with urgent need and no alternative options. Over the longer term, if safety and efficacy are established, the concept of a "universal donor" could be fully realized—organs that require no genetic matching and minimal immunosuppression, drastically reducing transplant waiting times and improving outcomes.

Moreover, the technologies developed for xenotransplantation may also feed back into allotransplantation (human-to-human). For example, CRISPR editing of human organs during ex vivo perfusion could "universalize" blood type or HLA status, making any donated organ suitable for any recipient. This would effectively end the problem of organ shortages due to immunological incompatibility. However, such approaches face significant technical challenges, including the need for rapid and thorough gene editing without damaging the organ, and the high cost of developing personalized editing protocols.

In conclusion, CRISPR technology is transforming the landscape of transplantation medicine by enabling the creation of genetically modified animal organs that can evade the human immune system. While obstacles related to safety, efficacy, and ethics remain, the first successful pig-to-human transplants have already demonstrated the potential of this approach. With continued investment in research, rigorous regulatory oversight, and open dialogue with the public, universal donor organs could become a reality within the next decade, saving countless lives and addressing one of the most critical challenges in modern medicine. For those interested in the latest developments, the National Human Genome Research Institute provides a clear overview of CRISPR and its therapeutic applications.